Fibrogen exercises exclusive license option for hifibio's ccr8 program

San francisco and cambridge, mass., dec. 20, 2021 (globe newswire) -- fibrogen, inc. (nasdaq: fgen), a leading biopharmaceutical company discovering, developing, and commercializing first-in-class therapeutics, and hifibio therapeutics, a private, multinational clinical-stage biotherapeutics company with expertise in immune modulation and single cell science, today announced an extension of their partnership with fibrogen's exercise of an exclusive license option for hifibio's anti-ccr8 monoclonal antibody program (hfb1011).
FGEN Ratings Summary
FGEN Quant Ranking